(3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone hydrochloride | 1198153-46-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone hydrochloride
• 英文别名: (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydropyrido[4,3-b][1,4]oxazin-4-yl)methanone hydrochloride；(3,5-Dibromo-4-hydroxy-phenyl)-(2,3-dihydro-pyrido[4,3-b][1,4]oxazin-4-yl)-methanone hydrochloric acid salt；(3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydropyrido[4,3-b][1,4]oxazin-4-yl)methanone;hydrochloride
• CAS: 1198153-46-6
• 化学式: C₁₄H₁₀Br₂N₂O₃*ClH
• 分子量: 450.514
• InChiKey: QFSCPXVNTZUIDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.77
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  62.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone hydrochloride 在 水 、 sodium hydroxide 作用下， 以60%的产率得到(3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone
  参考文献：
  名称：

  METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE

  摘要：

  公开号：

  EP3632917B1
• 作为产物：
  描述：

  (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone 在 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 0.5h， 以93.7%的产率得到(3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone hydrochloride
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVES

  摘要：

  本发明涉及杂环衍生物，更具体地，涉及用于制备治疗与尿酸相关疾病的药物的新颖杂环衍生物。

  公开号：

  US20110028467A1

文献信息

• Heterocyclic derivatives
  申请人：Ahn Sung Oh

  公开号：US08394792B2

  公开（公告）日：2013-03-12

  Disclosed are heterocyclic derivatives, and more particularly heterocyclic derivatives having the following Formula I which are useful for the preparation of medicaments for treating diseases related to uric acid: wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, L and Y are the same as defined in the detailed description.

  本发明涉及杂环衍生物，特别是具有以下式I的杂环衍生物，其对于制备治疗与尿酸相关疾病的药物是有用的： 式中R1、R2、R3、R4、R5、R6、R7、R8、X1、X2、X3、L和Y的定义与详细描述中定义的相同。
• METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND
  申请人：JW Pharmaceutical Corporation

  公开号：EP3632917A1

  公开（公告）日：2020-04-08

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。
• HYDROCHLORIDE SALT 1.5 HYDRATE OF AN HETEROCYCLIC DERIVATIVE COMPOUND
  申请人：JW Pharmaceutical Corporation

  公开号：EP3909956A1

  公开（公告）日：2021-11-17

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。
• A PHARMACEUTICAL COMPOSITION COMPRISING A HETEROCYCLIC DERIVATIVE FOR USE IN THE TREATMENT OF HYPERURICEMIA
  申请人：JW Pharmaceutical Corporation

  公开号：EP3909955A1

  公开（公告）日：2021-11-17

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。
• Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound
  申请人：JW PHARMACEUTICAL CORPORATION

  公开号：US20200207784A1

  公开（公告）日：2020-07-02

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.